Objective To explore the influencing factors of family participation in medication safety of aged patients with multi-morbidity,and to provide references for clinical practice.Methods Based on capability,opportunity and motivation-behavior model,17 family caregivers of aged patients with multi-morbidity at 8 communities of Zhengzhou,Henan Province from September to November 2024 were selected for semi-structured interviews using purposive sampling method.The data were analyzed using directed content analysis.Results Facilitators of family participation behavior included ability factors(strong self-reflection and emotional regulation ability),opportunity factors(family and peer support,professional support from medical staff),motivational factors(par-ticipation in medication safety importance perception,high level of participation self-efficacy,strong sense of responsibility).Barriers of family participation behavior included ability factors(the family caregivers'own aging and disease limitations,and the family caregivers'medication safety management ability is insufficient),opportunity factors(the excessive physical and mental independence of the patients,the multiple role conflict of the family caregivers).Conclusion There are some facilitators and barriers in the process of family participation in medication safety of elderly patients with multi-morbidity.Medical staff should attach importance to family participation experience,adopt targeted strategies to promote family participation in medication safety of elderly patients with multi-morbidity,so as to promote disease recovery.

Objective:To compare the clinical and laboratory characteristics and survival between Chinese and Western patients with myelodysplastic neoplasms (MDS) .Methods:Clinical and laboratory data were collected from 1,464 primary adult patients diagnosed with MDS at the Institute of Hematology & Blood Diseases Hospital from August 2016 to June 2024. Collected data were retrospectively analyzed and compared with 2,191 patients from the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM) .Results:Chinese patients were significantly younger (median age: 56 years vs. 72 years, P<0.001) and experienced more severe hematopenia ( P<0.001) compared with patients from the IWG-PM. Further, Chinese patients exhibited a higher percentage of isolated del (20q), +8, and complex karyotypes as well as a lower percentage of normal karyotypes, del (5q), and -Y ( P<0.001). Higher U2AF1, NRAS, and NPM1 mutation rates and lower ASXL1, SF3B1, and RUNX1 mutation rates were observed in Chinese patients than in participants from the IWG-PM ( P<0.05). No significant difference in overall survival (OS) was found between the two groups (median OS: 48 [95% CI: 40 - 56]months, vs. 45[95% CI: 40 - 49] months; P=0.449). Among participants aged ≤45 years, Chinese patients demonstrated more trisomy 8 ( P=0.070) and U2AF1 mutation ( P<0.001) and higher 4-year OS rate compared with those from the IWG-PM (75.5% vs. 62.1%, P=0.001). Among participants aged ≥70 years, Chinese patients exhibited more complex karyotypes but fewer del (5q) as well as more NPM1 but less SF3B1 and TET2 compared with those from the IWG-PM ( P<0.05). Chinese patients demonstrated shorter survival (median OS: 20 [95% CI: 13 - 27] months vs. 37 [95% CI: 32 - 42] months, P<0.001) . Conclusion:Chinese and Western MDS patients differ in age of onset, clinical features, and cytogenetic or molecular genetic abnormalities, with significant differences persisting in age-matched groups. Although the OS is similar, disparities exist in survival for younger and older patients between the two populations.

Objective:To identify the prognostic value of the Revised 15-item Myelodysplastic Syndrome-specific frailty scale (FS-15) in Chinese patients with myelodysplastic syndromes (MDS) .Methods:This retrospective study analyzed 812 patients with newly diagnosed MDS admitted to the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College from August 2016 to June 2023. Patients were assessed using the FS-15 and subsequently categorized into frail and non-frail groups. Clinical and laboratory characteristics, as well as overall survival (OS), were compared between these groups.Results:① The median patient age was 55 years ( IQR 45–64), with a median follow-up of 22.5 months (95% CI: 20.2–24.9) and a median OS of 43.3 months (95% CI: 36.8–49.8). The median FS-15 score was 0.42, with a cutoff value of 0.44. Male patients demonstrated higher median FS-15 scores than female patients (0.42 vs 0.38, P=0.006). In both the Revised International Prognostic Scoring System (IPSS-R; P=0.001) and Molecular International Prognostic Scoring System (IPSS-M; P=0.014) stratifications, FS-15 scores were significantly higher in the very high-risk group compared with the very low-risk group. ② The median OS was 54.7 months (95% CI: 47.5–NA) and 31.5 months (95% CI: 22.9–41.0) in the nonfrail ( n=452) and frail groups ( n=360), respectively ( P<0.001). The 3-year OS rates were (63.2 ± 3.2) % and (46.4 ± 3.6) % for the non-frail and frail groups, with 5-year OS rates of (49.9 ± 4.7) % and (32.0 ± 4.3) %, respectively ( P<0.001). ③Subgroup analysis revealed that nonfrail patients demonstrated significantly higher 3-year OS rates than frail patients in both the IPSS-M low-risk and very high-risk groups (all P<0.05). Similarly, nonfrail patients demonstrated superior 3-year OS rates compared with frail patients in the IPSS-R very low-risk, low-risk, and high-risk groups (all P<0.05). ④Among patients receiving hypomethylating agent therapy, the overall response rate was significantly higher in the non-frail group than in the frail group (86.7% vs 64.6%, P=0.007). Moreover, the frail group experienced higher rates of treatment-related adverse events, including febrile neutropenia (67.1% vs 47.4%, P=0.016) and liver function abnormalities (30.0% vs 14.5%, P=0.023), compared with the non-frail group. Conclusion:The FS-15 frailty score is a feasible and effective tool for assessing frailty in patients newly diagnosed with MDS in China and serves as a valuable prognostic indicator.

Objective:To investigate the clinical, laboratory, and prognostic features of myelodysplastic neoplasm (MDS) patients harboring acute myeloid leukemia (AML) -like mutations.Methods:We retrospectively analyzed clinical, molecular, and outcome data from 1 464 adults with primary MDS diagnosed at the Institute of Hematology and Blood Diseases Hospital from August 2016 to June 2024.Results:AML-like mutations were detected in 64 patients (4.4% ). Compared with patients without AML-like mutations, those with AML-like mutations were younger [median 50 ( IQR 39–60) vs 56 (45, 65) years; P=0.001], more often female (51.6% vs 35.4% ; P=0.009), had higher bone marrow blast percentage [6.5% (3.0%, 10.5% ) vs 2.5% (1.0%, 7.0% ) ; P<0.001], a higher rate of normal karyotype (75.0% vs 48.1% ; P<0.001), and lower hemoglobin levels [73 (67, 82) g/L vs 80 (66, 98) g/L; P=0.006]. The AML-like group had a higher number of gene mutations than the non-AML-like group [3 ( IQR 2–4) vs 2 (1, 3) ; P<0.001). It was enriched for mutations in NPM1, DNMT3A, WT1, PTPN11, NRAS, BCOR, FLT3, CEBPA, and MYC (all P<0.05) and had lower rates of U2AF1, ASXL1, and TP53 mutations (all P<0.05). Overall survival (OS) did not differ between groups ( P=0.730) ; however, the AML-like group had significantly shorter leukemia-free survival (LFS) [19 months (95% CI: 13–25) vs 46 months (95% CI: 38–54) ; P=0.012] and a higher 2-year cumulative incidence of AML transformation [ (41.7±9.1) % vs (10.4±1.1) % ; P<0.001]. Within the AML-like group, OS, LFS, and cumulative incidence of AML transformation did not differ between patients with low blasts and those with excess blasts (IB). Multivariable Cox regression identified age ≥60 years and PTPN11 mutations as independent adverse prognostic factors for OS, while DNMT3A, PTPN11, and FLT3 mutations independently predicted leukemic transformation. Conclusions:MDS patients harboring AML-like mutations exhibit distinct clinical and molecular features and a higher risk of progression to AML.

Objective To investigate the serum levels of CC chemokine ligand(CCL)8 and CCL22 in chil-dren with severe Mycoplasma pneumoniae pneumonia(SMPP)and their clinical significance.Methods A to-tal of 103 children with SMPP admitted to the hospital from January 2021 to June 2023 were selected as the SMPP group.According to the simplified pediatric critical illness score,they were divided into non-critical group(37 cases),critical group(40 cases),and extremely critical group(26 cases).According to the prognosis of 28 d after admission,the patients were divided into poor prognosis group(22 cases)and good prognosis group(81 cases).At the same time,a total of 60 children with mild Mycoplasma pneumoniae pneumonia(MMPP)were enrolled as the MMPP group,and 60 healthy children who underwent physical were enrolled as the control group.Enzyme-linked immunosorbent assay was used to detect serum levels of CCL8,CCL22,C-reactive protein(CRP),procalcitonin(PCT),tumor necrosis factor-α(TNF-α),and interleukin-6(IL-6).Pearson or Spearman correlation analysis was used to analyze the relationship between CCL8,CCL22 levels and CRP,PCT,TNF-α,IL-6 and the disease severity.Multivariate Logistic regression was used to analyze the influencing factors for the poor prognosis of children with SMPP.The receiver operating characteristic(ROC)curve was used to evaluate the value of CCL8 and CCL22 in predicting the poor prognosis of children with SMPP.Re-sults Compared with the control group,the levels of CCL8,CCL22,CRP,PCT,TNF-α and IL-6 were signifi-cantly increased in the SMPP group and MMPP group(P<0.05),and the levels of the above indexes in the SMPP group were significantly higher than those in the MMPP group(P<0.05).Compared with the non-critical group,the levels of CCL8,CCL22,CRP,PCT,TNF-α and IL-6 in the extremely critical group and the critical group were increased(P<0.05),and the levels of the above indexes in the extremely critical group were increased more significantly than those in the critical group(P<0.05).The levels of CCL8 and CCL22 in SMPP group were positively correlated with disease severity,CRP,PCT,TNF-α and IL-6(P<0.05).Com-pared with the good prognosis group,the levels of CCL8,CCL22,CRP,PCT,TNF-α and IL-6 in the poor prog-nosis group were increased(P<0.05).Increased serum levels of CRP,PCT,TNF-α,IL-6,CCL8,and CCL22 were independent risk factors for poor prognosis in children with SMPP(P<0.05).The area under the curve of serum CCL8,CCL22 and their combination for predicting poor prognosis was 0.807,0.801 and 0.907,re-spectively.The predictive value of combined detection of CCL8 and CCL22 was greater than that of each index alone(Z=1.811,1.864,P=0.029,0.025).Conclusion The serum levels of CCL8 and CCL22 are increased in children with SMPP,and are closely related to the severity and prognosis of the disease.Early combined de-tection of CCL8 and CCL22 can be used as a marker to predict the poor prognosis of children with SMPP.

In vitro,platelets are readily activated,which complicates the process of quality control.In con-trast,nanoparticles possess distinct advantages due to their small size,high surface area ratio,biocompatibili-ty,and modifiability.These properties enable them to inhibit platelet aggregation through encapsulation or multi-modification,thereby ensuring the stability of quality control products for clinical platelet assays.This paper delineates the properties of the two existent forms of platelet-nanoparticle complexes,their synthesis principles,and their applications in the medical field.The text goes on to examine the preparation methods of some platelet-nanoparticle complexes and their applications in the fields of cancer therapy,wound healing,and immune disorders.It also explores the potential relationship between platelet-nanoparticle complexes and exo-some-nanoparticle complexes.Additionally,the future research directions of nanoparticles in platelet plasmino-genics are discussed in this paper,emphasizing the effects of nanoparticle concentration,size,and surface modi-fication on platelet aggregation.This provides a theoretical basis for the development of stable and controllable platelet plasminogenics.

Many hematological disease prediction models built by big data analysis in medical laboratory and artificial intelligence (AI) technology, especially machine learning (ML) methods are reported more and more widely in researches on disease alerting, screening, diagnosis, discrimination, treatment and prediction. Because of a lack of guidance of standards, guidelines and normative documents in standardizing the construction and validation of these models, there is deficiency in model function, data preparation, screening and labeling, algorithm selection, model evaluation, as well as local and overall interpretation after model construction, which also limit the clinical application. Therefore, with integration of the literature review, combining the practice on blood disease prediction models, this article proposes that some keypoints and efficiency should be noticed, in order to build hematological diseases related models with clinical practical application value.

Objective:To analyze the values of platelet transforming growth factor-β (TGF-β) and SMAD family member 2 (Smad2) in patients′ peripheral platelets for CRC diagnosis and staging.Methods:Retrospective case-control study. Tumor tissues, paratumor tissues and peripheral blood samples were collected from 248 CRC patients (147 males, 101 females; age 21-93 years) diagnosed in the First Hospital of Jilin University from October 10th, 2020, to March 10th, 2025. Peripheral blood samples were also collected from 40 colorectal adenomatous polyp patients (21 males, 19 females; age 22-74 years) and 75 healthy individuals (43 males, 32 females; age 18-81 years) during the same period. Tissue homogenates and platelets were isolated using tissue disruption and gradient centrifugation, respectively. Total RNA was respectively extracted from tissues and platelets, and the expression levels of TGF-β and Smad2 were quantified by real-time fluorescence quantitative polymerase chain reaction (RT-qPCR) expressed as relative quantity 2 -ΔΔCt. Differences of TGF-β and Smad2 expression were compared between CRC tissues and adjacent tissues, as well as among CRC patients, polyp patients, and healthy controls. The relationship of platelet TGF-β and Smad2 expression with pathological features includingtumor stage, pathological type, and metastasis were analyzed. The efficiency of platelet TGF-β, Smad2, and their combination in diagnosing CRC was evaluated using receiver operating characteristic (ROC) curves. Results:The expression levels of TGF-β and Smad2 in CRC tumor tissues[1.09 (0.45, 2.00), 2.93 (0.78, 6.73)] were significantly higher than those in adjacent tissues[0.81 (0.27, 1.50), 1.29 (0.40, 2.63)] ( Z TGF-β=4.54, Z Smad2=6.67, both P<0.001). The expression levels of TGF-β and Smad2 in platelets of CRC patients[2.73(1.53, 4.38), 3.16 (1.58, 4.38)] were significantly higher than those in the colorectal polyp group[1.23(0.70, 2.54), 1.16(0.78, 2.27)] and the healthy control group[0.96(0.51, 1.88), 0.92 (0.55, 1.88)] ( H TGF-β=59.71, H Smad2=78.74, both P<0.001). Platelet TGF-β expression increased progressively with tumor stage (stage 1-4) ( P<0.05), while platelet Smad2 levels were higher in metastatic CRC compared with non-metastatic cases ( P<0.05). ROC curve analysis showed that the area under the curve (AUC) for diagnosing CRC when combining platelet TGF-β and Smad2 was 0.81[95%Confidence interval( CI) 0.77—0.86], which was 0.90 (95% CI 0.86—0.93) if adding serum carcinoembryonic antigen (CEA). Conclusion:Platelet TGF-β and Smad2 expression correlates with the diagnosis and staging of CRC, demonstrating potential as liquid biopsy biomarkers for colorectal malignancies.

Objective:To establish and optimize the cutoff values of D-dimer (D-D) for excluding suspected acute pulmonary embolism (APE).Methods:A retrospective cross-sectional study was conducted by recruiting a total of 428 patients with suspected APE complaining of chest pain, hemoptysis, dyspnea, etc., who underwent computed tomography pulmonary angiography (CTPA) in the Emergency Department of the First Hospital of Jilin University from January 1st, 2022, to October 31st, 2024, taken as observation group. The Median age was 64.0 (55.0, 72.0) years old with male and female 214 respectively. Data collection included clinical manifestations(hemoptysis, swelling and pain in the lower limbs), deep vein thrombosis (DVT) history, Wells scores, laboratory results, CTPA and vascular ultrasound foundings. According to CTPA results, observation group was divided into APE group (233 cases) and non-APE group (195 cases); according to Wells scoring, observation group was divided into APE at low, moderate, or high pre-test probability subgroups. Meanwhile, 196 healthy individuals in the same period were included as the health control group. D-D levels were compared among different groups. Receiver operating characteristic (ROC) curve analysis was used to determine the D-D cutoff values for excluding APE, and the area under the curve (AUC) and negative predictive value (NPV) were evaluated.Results:D-D levels in the CTPA-APE group, CTPA-non APE group, and the healthy control group were [7.77 (4.10, 16.58)] mg/L, [0.53 (0.24, 0.94)] mg/L, and [0.21 (0.15, 0.32)] mg/L, respectively, with statistically significant differences ( P<0.05). In the APE group, D-D levels within low-, moderate-, and high-probability subgroups were [7.48 (3.87, 15.85)] mg/L, [7.92 (4.08, 13.90)] mg/L, and [21.39 (7.92, 89.68)] mg/L, respectively, with statistically significant differences among subgroups ( P<0.05), while no significant difference between low-and moderate-probability subgroups ( P>0.05). For suspected APE with low-probability, exclusive D-D level was 0.62 mg/L with AUC and NPV at 1.000 and 100% taking healthy control group as negative control, and 1.65 mg/L with AUC and NPV at 0.989 and 94.00% taking non-APE group as negative control, while the optimized D-D level was 1.10 mg/L adjusted by NPV ≥98%. For suspected APE with low to moderate-probability, the exclusive D-D level was 0.55 mg/L with AUC and NPV at 0.997 and 99.00% taking healthy control group as negative control, and 1.64 mg/L with AUC and NPV at 0.979 and 92.60%, while the optimized D-D level was 0.55 mg/L adjusted by NPV ≥98%. Conclusion:This study established and optimized the exclusive diagnostic cutoff value of D-D for suspected APE in Emergency Department integrated with the Wells scoring, which may effectively reduce the false-positive rate while improve the clinical application for APE exclusion using D-D.

Objective:To validate and optimize the interpretation methods and cut-off values of prolonged activated partial thromboplastin time (APTT) mixing test, in order to elevate the clinical applicational value in differentiating single factor deficiency, positive lupus anticoagulant (LA) and FⅧ inhibitors.Methods:This cross-sectional retrospective study involved 130 cases with single APTT prolongation for unknown reasons who underwent mixing tests in the First Hospital of Jilin University from January 1st, 2022 to December 31st, 2023, including 84 males and 46 females. Rosner index (RI), Percentage correction ("Chang") method, Normal reference interval (NRI) method, differential analysis, post-incubation prolongation time and percentage (including mixed immediately and ) were respectively calculated and analyzed for both immediate mixing and 2-hour post-mixing incubation. According to clinical diagnosis, patients were divided into single factor deficiency (51 cases), positive lupus anticoagulant (LA) (56 cases), and positive factor Ⅷ (FⅧ) inhibitor (23 cases). Receiver operation characteristic (ROC) curve analysis was used to determine the cut-off values for APTT mixing test methods in patients with different reasons for prolonged APTT, which were evaluted and adjusted by AUC, sensitivity, and specificity, and compared with the methods currently used for interpretations.Results:For the single factor deficiency cases, the AUCs of immediate RI index <7.5% and incubated RI index <13.9% were 0.87 and 0.90, respectively, with sensitivities at 87.8% and 83.8%, and specificities at 72.0% and 80.0%, whose combination had sensitivity and specificity at 87.3%, and 94.0%, respectively; the judging accuracy increased from 84.6% (110/130) in currently used rule to 93.1% (121/130). For the positive lupus anticoagulant (LA) cases, the combination of immediate RI index >10.3% and prolonged post-incubation clotting time percentage <9.1% showed 88.5% sensitivity and 99.8% specificity; the judging accuracy improved from 80.0% (104/130) in currently used rule to 86.2% (112/130). For positive FⅧ inhibitor cases, the combination of incubated RI index >17.0% and prolonged post-incubation clotting time percentage >9.1% had 99.8% sensitivity and 100.0% specificity; the judging accuracy increased from 89.2% (116/130) in currently used rule to 94.6% (123/130).Conclusion:This study validated and optimized the interpretation methods and cut-off values for the prolonged APTT mixing test in differentiating single factor deficiencies, prositive FⅧ inhibitors and LA positive cases, significantly improving the judging sensitivity and specificity.